Neeraj Agarwal, MD:What do I do when this patient experiences disease progression on cabozantinib? I think I base my decision or therapy selection for the second line, when second-line therapy is concerned, on the volume of disease or rapidity of disease progression. If the disease is progressing mildlythe pace is slow, indolent—I would choose nivolumab, because then I’m not really worried about not experiencing a progression-free survival benefit with nivolumab.
On the other hand, if this disease is rapidly progressing with multiple new lesions, including liver lesions, on cabozantinib, I would choose the lenvatinib/everolimus combination, because that combination has been shown to have remarkably high rates of objective response, which have not been seen by any other monotherapy so far in metastatic renal cell carcinoma.
Transcript edited for clarity.
Case Scenario: A 73-year old female with rapidly progressing mRCC
March 2017
December 2017
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC
July 8th 2024During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.
Read More